Haijiao Zhang

Haijiao Zhang

Auto-generated profile, based on publicly available information

Haijiao Zhang

Division of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, OR

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2020 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
HZHaijiao Zhang
Haijiao Zhang
YNYusuke Nakauchi
Yusuke Nakauchi
TKThomas Köhnke
Thomas Köhnke
MSMelissa Stafford
Melissa Stafford
DBDaniel Bottomly
Daniel Bottomly
JTJeffrey W. Tyner
Jeffrey W. Tyner

12 September 2019 in Blood
Verified
Journal Article
Open access
PDF file
HZHaijiao Zhang
Haijiao Zhang
BWBeth Wilmot
Beth Wilmot
DBDaniel Bottomly
Daniel Bottomly
KDKim-Hien T. Dao
Kim-Hien T. Dao
ESEmily Stevens
Emily Stevens
JTJeffrey W. Tyner
Jeffrey W. Tyner
Chronic neutrophilic leukemia (CNL), atypical chronic myeloid leukemia (aCML), and myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN-U) are a group of rare and heterogeneous myeloid disorders. There is strong morphologic resemblance among these distinct diagnostic entities as well as a lack of specific molecular markers and limited understanding of disease pathogenesis, which has made diagnosis challenging in certain cases. The treatment has remained empirical, resulting in dismal outcomes. We, therefore, performed whole-exome and RNA sequencing of these rare hematologic malignancies and present the most complete survey of the genomic landscape of these diseases to date. We observed a diversity of combinatorial mutational patterns that generally do not cluster within any one diagnosis. Gene expression analysis reveals enrichment, but not cosegregation, of clinical and genetic disease features with transcriptional clusters. In conclusion, these groups of diseases represent a continuum of related diseases rather than discrete diagnostic entities.

7 June 2022 in Journal of Colloid and Interface Science
Verified
Journal Article
Closed access
HZHaijiao Zhang
Haijiao Zhang
SYShuo Yao
Shuo Yao
RSRen Sheng
Ren Sheng
JWJuan Wang
Juan Wang
HLHang Li
Hang Li
CZChao Zhao
Chao Zhao

22 May 2025 in Blood
Verified
Journal Article
Closed access
BABasil Allen
Basil Allen
DBDaniel Bottomly
Daniel Bottomly
TKThomas Köhnke
Thomas Köhnke
AWAnthony Wang
Anthony Wang
HLHsin-Yun Lin
Hsin-Yun Lin
HZHaijiao Zhang
Haijiao Zhang
Abstrat: MDM2 inhibitors are promising therapeutics for acute myeloid leukemia (AML) with wild-type TP53. Through an integrated analysis of functional genomic data from primary patient samples, we found that an MDM2 inhibitor, idasanutlin, like venetoclax, is ineffective against monocytic leukemia (French-American-British [FAB] subtype M4/M5). To dissect the underlying resistance mechanisms, we explored both intrinsic and extrinsic factors. We found that monocytic leukemia cells express elevated levels of CEBPB, which promote monocytic differentiation, suppress CASP3 and CASP6, and upregulate MCL1, BCL2A1, and the interleukin (IL-1)/tumor necrosis factor alpha (TNF-α)/NF-κB pathway members, thereby conferring drug resistance to a broad range of MDM2 inhibitors, BH3 mimetics, and venetoclax combinations. In addition, aberrant monocytes in M4/M5 leukemia produce elevated levels of IL-1 and TNF-α, which promote monocytic differentiation and upregulate inflammatory cytokines and receptors, thereby extrinsically protecting leukemia blasts from venetoclax and MDM2 inhibition. Interestingly, IL-1β and TNF-α only increase CEBPB levels and protect M4/M5 cells from these drugs but not M0/M1 leukemia cells. Treatment with venetoclax and idasanutlin induces compensatory upregulation of CEBPB and the IL-1/TNF-α/NF-κB pathway independent of the FAB subtype, indicating drug-induced compensatory protection mechanisms. The combination of venetoclax or idasanutlin with inhibitors that block the IL-1/TNF-α pathway demonstrates synergistic cytotoxicity in M4/M5 AML. As such, we uncovered a targetable positive feedback loop that involves CEBPB, IL-1/TNF-α, and monocyte differentiation in M4/M5 leukemia and promotes both intrinsic and extrinsic drug resistance and drug-induced protection against venetoclax and MDM2 inhibitors.

14 May 2023 in British Journal of Haematology
Verified
Journal Article
Closed access
LSLindsey Savoy
Lindsey Savoy
NLNicola Long
Nicola Long
HLHyunjung Lee
Hyunjung Lee
RCReid Chen
Reid Chen
BABasil Allen
Basil Allen
HZHaijiao Zhang
Haijiao Zhang

12 June 2024 in British Journal of Haematology
Verified
Journal Article
Closed access
BABasil Allen
Basil Allen
LSLindsey Savoy
Lindsey Savoy
PRPeter Ryabinin
Peter Ryabinin
DBDaniel Bottomly
Daniel Bottomly
RCReid Chen
Reid Chen
HZHaijiao Zhang
Haijiao Zhang